DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

School of Pharmaceutical Sciences, University of Geneva, 1206 Geneva, Switzerland Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

In other words, "the cannabinoid receptors were seen to be activated and the acetylcholine levels in the brain to be increased. The drug restored the cholinergic system and improved memory", added ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

1 Department of Neurology, Wuhan No. 1 Hospital, Wuhan, China 2 The First Clinical Medical Institute, Hubei University of Chinese Medicine, Wuhan, China Introduction/Aims: Myasthenia Gravis (MG) is a ...

These compounds are: NBI-1117570 (a dual M1 / M4 agonist) NBI-1117567 (an M1-preferring agonist) NBI-1117569 (an M4-preferring agonist) Nxera and Neurocrine entered a collaboration and licensing ...